In support of their submission, the Parties explain that:
The main suppliers of dairy enzymes are global players with the same products sold across the globe – and often under the same brand;
The main customers purchase dairy enzymes globally;
(iii)There are no significant barriers to cross-border trade of dairy enzymes across regions and continents. The Parties mention low transport costs in relation to the total cost of production85 as well as low import duties.
86 They also submit that there are no trade barriers except for product registration requirements in relevant regions and countries. With regards to the regulatory framework, the Parties mention that in all major jurisdictions, regulatory approvals are generally linked to the molecule and therefore, at the commercialization/distribution level, no new regulatory approval is needed.
However, the Parties submit that the EU/EEA legal framework87 applies to all products marketed and sold within the EU/EEA irrespective of whether these products are manufactured and sold within the EU/EEA or imported into and sold on the EU/EEA market. Thus, the Parties are not aware of any relevant regulatory framework applicable in the EU/EEA only related to products imported from third countries;
Many players have to ship their products globally;
Novozymes and Chr. Hansen’s pricing towards end-customers follow [information on pricing];
90 and (vi)The structure of supply and demand of dairy enzymes and of competition between the relevant suppliers are global in scope.91